HENRY FRIEDMAN, M.D.
Medical Practice at Erwin Rd, Durham, NC

5523084, Jun 4, 1996

Sep 7, 1994

8/301769

Darell D. Bigner - Mebane NC
Henry S. Friedman - Durham NC
Owen W. Griffith - Milwaukee WI

Cornell Research Foundation, Inc. - Ithaca NY
Duke University - Durham NC

A61K 3748, A61K 3750, A61K 31195, A61K 39395

424 944

L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan. Preferably anti L-amino acid oxidase antibody is administered intermediate the L-amino acid oxidase and melphalan administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the melphalan transport improving plasma level reduction of large neutral amino acids thereby to reduce or eliminate degrading of melphalan by L-amino acid oxidase.

5695751, Dec 9, 1997

Sep 21, 1995

8/531586

Henry S. Friedman - Durham NC
Darell D. Bigner - Mebane NC
Owen W. Griffith - Milwaukee WI

Cornell Research Foundation, Inc. - Ithaca NY
Duke University - Durham NC

A61K 3844, A61K 31195

424 944

L-amino acid oxidase is utilized to reduce the plasma level of large neutral amino acids to allow the opportunity of increased large neutral amino acid drug transport across the blood brain barrier. Preferably anti L-amino acid oxidase antibody is administered intermediate to the L-amino acid oxidase and large neutral amino acid drug administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the large neutral amino acid drug transport improving level plasma reduction of large neutral amino acids thereby to reduce or eliminate degrading of large neutral amino acid drugs by L-amino acid oxidase. The large neutral amino acid drugs include levodopa, melphalan, L-DON, azaserine, acivicin, L-alanosine and 3-(phosphonomethyl)phenylalanines. For treatment of brain tumors, the drug administration is preferably preceded by the administration of a large neutral amino acid glutathione depleting agent, e. g. , L-buthionine-SR-sulfoximine.

6251886, Jun 26, 2001

Dec 2, 1999

9/453747

Henry S. Friedman - Durham NC

Schering Corporation - Kenilworth NJ

A61K 3133

514183

Methods are disclosed for treating cancer in a patient in need of such treating comprising administering temozolomide in an amount effective to achieve a clinical response wherein the temozolomide is administered in a microcrystalline suspension.

5407672, Apr 18, 1995

Apr 8, 1993

8/046866

Owen W. Griffith - Milwaukee WI
Henry S. Friedman - Durham NC

Cornell Research Foundation, Inc. - Ithaca NY
Duke University - Durham NC

A61K 3750, A61K 3748, A61K 31195

424 944

L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan.

5407925, Apr 18, 1995

Nov 6, 1991

7/788609

Darell D. Bigner - Chapel Hill NC
Henry S. Friedman - Durham NC
O. Michael Colvin - Baltimore MD

The Johns Hopkins University - Baltimore MD
Duke University - Durham NC

A61K 3166

514110

A method of treating human tumors is provided in which tumors are regionally treated with a cytolytic, pre-activated, bifunctional alkylating agent, namely 4-hydroperoxycyclophosphamide. The treatment is effective against a variety of tumor types within the central nervous systems.